Peter Lynch fit · Growth at a reasonable price (GARP)
Is Arbutus Biopharma Corporation (ABUS) a Peter Lynch Stock?
Does not fit Lynch's GARP criteria - growth too low or price too high.
11/100
FNão encaixa
1/6 critérios atendidos
Os critérios de Peter Lynch, aplicados a ABUS
PEG ≤ 1.0
chave-
EPS CAGR ≥ 15%
chave-
Revenue CAGR ≥ 10%
6.4%
Net margin > 0
-237.9%
Como ABUS pontua em outras estratégias
Dados financeiros ao vivo
Cap. de mercado
$859.29M
P/L (TTM)
5.1x
ROIC (TTM)
56.72%
Margem bruta
99.98%
Outras análises Peter Lynch
Perguntas frequentes
What is ABUS's Peter Lynch fit score?
ABUS scores 11/100 on our Peter Lynch fit engine - grade F. Does not fit Lynch's GARP criteria - growth too low or price too high.
Does Peter Lynch actually own ABUS?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends ABUS.
How often is this score updated?
ABUS's Peter Lynch fit score is recomputed daily from the latest TTM financials. The page below shows when it was last refreshed.
Ferramenta educacional, não é consultoria de investimento. As pontuações são calculadas a partir de dados financeiros públicos contra os critérios publicados de cada estratégia de investimento. Não afirmamos que Peter Lynch possua ou recomende ABUS pessoalmente.